Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis Group
2024-12-01
|
| Serie: | Human Vaccines & Immunotherapeutics |
| Soggetti: | |
| Accesso online: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2387221 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|